H

HCA

HCA

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
6%Bearish
Buy/Sell Ratio0% buys
BearishBullish
HCA Live QuoteReal-time
$460.33
+$0.93(+0.20%)1M
Day Range$459.30 – $475.47
Open$472.99
Previous Close$476.35
Volume1.42M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$96.16B
P/E Ratio (TTM)15.8
Forward P/E15.2
EPS (TTM)$29.14
Price to Book291.3
Dividend Yield0.64%
Beta (Volatility)1.10
IndustryMEDICAL CARE FACILITIES
52-Week RangeCurrent: $460.33 (53%)
Low: $353.34High: $553.56
Wall Street Consensus
Strong Buy
Analyst Rating
4.8/ 5.0
Target Price
$485.68+223.8% upside

Insider Buys

1

$88K

Insider Sales

16

$62.85M

Total Volume

$62.94M

17 transactions

Net Activity

$62.76M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
15CONFIDENCE

Sentiment Rating

Heavy Distribution

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
  • •Significant liquidation: total sale value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
F
1

Foster Jon M

EVP, COO

0 buys2 sells

$21.69M total

H
2

Hazen Samuel N

CEO

0 buys1 sells

$21.48M total

B
3

Berres Jennifer

SVP, Chief Human Res. Officer

0 buys2 sells

$7.20M total

M
4

McAlevey Michael R

EVP, Chief Legal, Admin Office

0 buys2 sells

$2.75M total

C
5

Cuffe Michael S.

EVP, Chief Clinical Officer

0 buys2 sells

$2.35M total

Trading History
HCA insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Nov 10, 2026

1 weeks ago

Rossitto Erica

SVP, Chief Nurse Exec

SVP
Sell3.5K$505.81$1.77M

Nov 4, 2026

2 weeks ago

Schlosser Michael J

EVP, Chief Clinical Officer

EVP
Sell1.2K$494.65$594K

Nov 4, 2026

2 weeks ago

Foster Jon M

EVP, COO

COO
Sell31.7K$500.98$15.89M

Feb 18, 2026

9 months ago

McAlevey Michael R

EVP, Chief Legal, Admin Office

EVP
Sell1.7K$533.38$904K

Feb 11, 2026

9 months ago

Berres Jennifer

SVP, Chief Human Res. Officer

SVP
Sell8.0K$514.58$4.13M

Feb 11, 2026

9 months ago

Wyatt Christopher F.

SVP, Controller

SVP
Sell4.0K$505.00$2.02M

Feb 3, 2026

9 months ago

Cuffe Michael S.

EVP, Chief Clinical Officer

EVP
Sell1.5K$498.09$747K

Feb 3, 2026

9 months ago

Hazen Samuel N

CEO

CEO
Sell42.9K$501.04$21.48M

Nov 5, 2025

12 months ago

McAlevey Michael R

EVP, Chief Legal, Admin Office

EVP
Sell3.9K$473.79$1.84M

Sep 8, 2025

14 months ago

Cuffe Michael S.

EVP, Chief Clinical Officer

EVP
Sell3.8K$418.84$1.61M

May 13, 2025

18 months ago

Foster Jon M

EVP, COO

COO
Sell15.7K$369.33$5.80M

Jan 10, 2012

180 months ago

Bank of America Corp /de/

10%

10% Owner
Sell3.2K$25.12$80K

Jul 26, 2011

186 months ago

Bank of America Corp /de/

10%

10% Owner
Buy3.4K$25.67$88K

Feb 14, 2025

21 months ago

Berres Jennifer

SVP, Chief Human Res. Officer

SVP
Sell9.5K$322.59$3.08M

Nov 14, 2024

24 months ago

Whalen Kathleen M

SVP, Chief Ethics Officer

SVP
Sell1.5K$357.99$528K

Nov 14, 2024

24 months ago

Akdamar Erol R

Group Pres

President
Sell2.9K$353.00$1.02M

Nov 14, 2024

24 months ago

Billington Phillip G

SVP-Internal Audit Services

SVP
Sell3.9K$350.00$1.36M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
HCA Buy Conviction0%
Industry Rank#98 of 570
Volume Contribution0.4%
Total Industry Activity$16.52B

HCA has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. HCA ranks #98 in insider activity out of 570 tracked companies in its industry.

Insider Trading Summary & Commentary
Automated executive transaction analysis for HCA

Over the last 90 days, corporate insiders at HCA (HCA) engaged in a total of 17 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 16 were sales. The total volume of insider trading reached $62.94M.

The net insider activity for HCA shows a net selling bias of $62.76M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Hazen Samuel N (CEO), who traded 42.9K shares valued at $21.48M on Feb 3, 2026.

Live Market News & Developments
Aggregated real-time headlines for HCA (HCA)
6 updates

HCA Healthcare Inc. stock outperforms competitors despite losses on the day

MarketWatchYesterday

HCA Healthcare (HCA) Stock May Be 46% Undervalued Following Cape Coral Hospital Incentives

Yahoo Finance24d ago

HCA stock rebounds after dipping on financial report

Nashville Post22d ago

Hca Holdings Stock Price Forecast. Should You Buy HCA?

StockInvest.us13d ago

HCA Healthcare (HCA) Stock Forecast and Price Target 2026

MarketBeat2d ago

What Really Drove HCA Stock Higher?

Trefis9d ago

FAQs About HCA Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for HCA.

Based on SEC Form 4 disclosures, the Insider Confidence Score for HCA is currently 15/100, which reflects a heavy distribution bias. This calculation accounts for a total of 1 purchases and 16 sales by company executives over the last 90 days.

The CEO Conviction Index for HCA is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.